华邦生命健康股份有限公司 2025 年半年度财务报告 华邦生命健康股份有限公司 2025 年半年度财务报告 2025 年 8 月 1 华邦生命健康股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 编制单位：华邦生命健康股份有限公司 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 3,669,356,017.47 | 3,289,723,455.66 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 846,937,613.89 | 653,871,945.86 | | 衍生金融资产 | | | | 应收票据 | 185,913,566.60 | 75,173,492.02 | | 应收账款 | 2,360,957,720.98 | 2,169,960,063.82 | | 应收款项融资 | 400,506,043.08 | 294,685,115.45 | | ...

华邦生命健康股份有限公司2025年1-6月非经营性资金占用及其他关联资金往来情况汇总表 编制单位：华邦生命健康股份有限公司 单位：人民币万元 法定代表人：张松山 主管会计工作负责人：王剑 会计机构负责人：王剑 附表1： | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的 | 2025年期初往 | 2025年1-6月往来累计 | 2025年1-6月往 | 2025年1-6月偿还 | 2025年6月30日往 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 会计科目 | 来资金余额 | 发生金额(不含利息) | 来资金的利息 (如有) | 累计发生金额 | 来资金余额 | | | | 控股股东、实际控制 | | | | | | | | - | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | | - - | | | - | - | | | | 前控股股东、实际控 | | | | | ...

证券代码：002004 证券简称：华邦健康 公告编号：2025039 华邦生命健康股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025 年第一次临时股东会。 6、会议的股权登记日：2025 年 9 月 2 日（星期二）。 7、出席对象： （1）在股权登记日持有公司股份的股东或其代理人，即于 2025 年 9 月 2 日（星期二，股权登记日）下午收市时在中国证券登记结算有限公司深圳分公司 登记在册的公司全体股东均有权出席股东会，并可以书面形式委托代理人出席会 议和参加表决，该股东代理人不必是本公司股东（授权委托书见附件二）； 2、股东会的召集人：公司董事会。 华邦生命健康股份有限公司（以下简称"公司"）第九届董事会第二次会议于 2025 年 8 月 18 日召开，审议通过了《关于召开 2025 年第一次临时股东会的议 案》。 3、会议召开的合法、合规性：本次股东会的召集和召开符合《公司法》、 《上市公司股东会规则》等法律、法规、规范性文件及《公司章程》、《股东 ...

证券代码：002004 证券简称：华邦健康 公告编号：2025036 华邦生命健康股份有限公司 第九届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开及议案审议情况 华邦生命健康股份有限公司（以下简称"公司"）第九届董事会第二次会议通 知于 2025 年 8 月 14 日以电子邮件的形式发出，2025 年 8 月 18 日通过通讯表决 的形式召开，公司 6 名董事都参加了本次会议，会议的通知及召开符合《公司法》 及《公司章程》的规定，合法有效。会议由董事长张松山先生主持，经与会各位 董事认真讨论研究，审议通过了以下议案： （一）会议以 6 票赞成、0 票反对、0 票弃权的表决结果审议通过了《<2025 年半年度报告>及其摘要》。 详见公司于同日刊载在《中国证券报》、《证券时报》、《上海证券报》、 巨潮资讯网（www.cninfo.com.cn）的《2025 年半年度报告摘要》（公告编号： 2025037）和刊载在巨潮资讯网（www.cninfo.com.cn）的《2025 年半年度报告》。 （二）会议以 6 票赞成、0 票 ...

[Important Notice, Table of Contents, and Definitions](index=2&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA%E3%80%81%E7%9B%AE%E5%BD%95%E5%92%8C%E9%87%8A%E4%B9%89) This section provides crucial disclaimers, outlines the report structure, and defines key terms for clarity [Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) The company's board and senior management guarantee the report's truthfulness, accuracy, and completeness, assuming legal responsibility, with all directors attending the review meeting - The company's board and senior management ensure the report's authenticity, accuracy, and completeness, bearing corresponding legal liabilities[5](index=5&type=chunk) - The company approved the 2025 half-year profit distribution plan, proposing a cash dividend of **CNY 2.0 (tax inclusive) per 10 shares**[6](index=6&type=chunk) [Definitions](index=5&type=section&id=%E9%87%8A%E4%B9%89) This chapter defines key abbreviations for the company and its associated entities, such as "Huabong Pharma," "Yingtai Bio," and "Kaisheng New Materials," providing a foundation for understanding the report's content - The report clarifies abbreviations for the company and its major holding and participating subsidiaries, facilitating investor comprehension of various business entities[13](index=13&type=chunk) [Company Profile and Key Financial Indicators](index=6&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) This section introduces the company's basic information and presents its key financial performance metrics for the reporting period [Company Profile](index=6&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B) Huabong Life Health Co Ltd (stock code: 002004) is a company listed on the Shenzhen Stock Exchange, with Zhang Songshan as its legal representative, and its contact information and disclosure locations remained unchanged during the reporting period Company Basic Information | Item | Information | | :--- | :--- | | Stock Abbreviation | Huabong Health | | Stock Code | 002004 | | Listing Exchange | Shenzhen Stock Exchange | | Legal Representative | Zhang Songshan | [Key Accounting Data and Financial Indicators](index=7&type=section&id=%E5%9B%9B%E3%80%81%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In the first half of 2025, the company's operating revenue slightly increased by 0.39% year-on-year, while net profit attributable to the parent company grew significantly by 23.90%, and net cash flow from operating activities surged by 46.10%, indicating improved profitability and cash flow management Key Financial Performance | Key Financial Indicator | Current Reporting Period | Prior Year Period | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue (CNY) | 5,945,032,088.09 | 5,922,042,354.85 | 0.39% | | Net Profit Attributable to Listed Company Shareholders (CNY) | 388,455,625.50 | 313,522,665.65 | 23.90% | | Net Cash Flow from Operating Activities (CNY) | 536,502,508.00 | 367,219,592.32 | 46.10% | | Basic Earnings Per Share (CNY/share) | 0.1969 | 0.1586 | 24.15% | | Weighted Average Return on Net Assets | 4.07% | 3.08% | 0.99% | | Total Assets (CNY) | 29,654,478,331.32 | 29,450,469,334.61 | 0.69% (vs. end of prior year) | | Net Assets Attributable to Listed Company Shareholders (CNY) | 9,748,372,423.62 | 9,337,058,173.60 | 4.41% (vs. end of prior year) | [Non-Recurring Gains and Losses](index=7&type=section&id=%E5%85%AD%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%8F%8A%E9%87%91%E9%A2%9D) During the reporting period, the company's non-recurring gains and losses totaled CNY 40.86 million, primarily from government grants, disposal of non-current assets, and other non-operating income and expenses, contributing to current net profit but with limited sustainability Non-Recurring Items | Item | Amount (CNY) | | :--- | :--- | | Gains/Losses from Disposal of Non-Current Assets | 8,922,978.09 | | Government Grants Included in Current Profit/Loss | 29,889,588.05 | | Fair Value Changes and Disposal Gains/Losses of Financial Assets/Liabilities | 7,896,438.05 | | Other Non-Operating Income and Expenses | 27,202,515.53 | | **Total** | **40,858,400.76** | [Management Discussion and Analysis](index=9&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) This section provides a comprehensive analysis of the company's operational performance, financial condition, and future outlook [Overview of Principal Businesses](index=9&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E4%BB%8E%E4%BA%8B%E7%9A%84%E4%B8%BB%E8%A6%81%E4%B8%9A%E5%8A%A1) The company focuses on the grand health industry, with businesses spanning pharmaceuticals, medical services, agrochemicals, new materials, and tourism; in H1 2025, it achieved CNY 5.945 billion in revenue (+0.39%) and CNY 388 million in net profit attributable to the parent (+23.90%), primarily driven by a recovery in agrochemical and new materials sectors and cost optimization, while pharmaceutical and tourism segments faced challenges - The company's business model is centered on grand health, featuring a diversified development approach with three listed subsidiaries: Yingtai Bio, Kaisheng New Materials, and Lijiang Co Ltd[27](index=27&type=chunk) Key Financial Metrics (H1 2025) | Financial Indicator | H1 2025 Amount (million CNY) | YoY Growth | | :--- | :--- | :--- | | Operating Revenue | 5,945.03 | 0.39% | | Operating Profit | 666.68 | 18.55% | | Net Profit Attributable to Parent | 388.46 | 23.90% | | Net Profit Attributable to Parent (Excl. Non-Recurring) | 347.60 | 17.62% | [Pharmaceutical Business](index=9&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E5%8C%BB%E8%8D%AF%E4%B8%9A%E5%8A%A1) The pharmaceutical business covers formulations and APIs in dermatology, anti-infectives, and oncology; during the reporting period, several new products, including the first generic Calcipotriol Betamethasone Ointment, received market approval, and the company leverages its "API + Formulation" integrated model to navigate centralized procurement policies and expand through production base upgrades and marketing channel development - During the reporting period, **6 formulation products**, including Calcipotriol Betamethasone Ointment, received marketing approval, with the latter being the **first generic and first to pass consistency evaluation in China** for psoriasis treatment, marking a significant breakthrough[28](index=28&type=chunk) - The company adheres to an **"API + Formulation" integrated strategy**, with its own API bases ensuring core product supply and mitigating the impact of centralized procurement policies[34](index=34&type=chunk) [Medical Business](index=11&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E5%8C%BB%E7%96%97%E4%B8%9A%E5%8A%A1) The medical business has established a "Medical + Health" ecosystem encompassing basic medical care, rehabilitation, and health and longevity medicine, with institutions like Chongqing Songshan Hospital and Beijing Huasheng Rehabilitation Hospital developing steadily, increasing bed capacity, and actively exploring precision medicine and full-lifecycle health management services - Beijing Huasheng Rehabilitation Hospital's approved bed count increased from **300 to 457**, with steady growth in patient visits[29](index=29&type=chunk)[37](index=37&type=chunk) - The company actively explores precision medicine and full-lifecycle health management, with the opening of Beijing Paracelsus Clinic during the reporting period expanding its health and longevity medicine services[29](index=29&type=chunk)[37](index=37&type=chunk) [Agrochemical Business](index=12&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%E5%86%9C%E5%8C%96%E4%B8%9A%E5%8A%A1) The agrochemical business encompasses R&D, production, and sales of pesticide technicals, intermediates, and formulations; despite overall low industry prices, the sector experienced a partial recovery driven by the Northern Hemisphere's spring planting season and overseas restocking demand, leading to a stabilization of the company's agrochemical segment profitability - During the reporting period, the domestic pesticide industry remained affected by supply-demand imbalance, but a rebound in overseas restocking demand led to a partial industry recovery, stabilizing the company's agrochemical segment performance[29](index=29&type=chunk) [New Materials Business](index=13&type=section&id=%EF%BC%88%E5%9B%9B%EF%BC%89%E6%96%B0%E6%9D%90%E6%96%99%E4%B8%9A%E5%8A%A1) The new materials business primarily engages in the R&D, production, and sales of fine chemical products and novel polymer materials (such as PEKK); during the reporting period, the segment's performance significantly increased year-on-year, benefiting from the recovery in agrochemical demand and low raw material prices, which boosted both shipment volumes and gross margins of key products - Benefiting from a rebound in agrochemical demand and low liquid chlorine raw material prices, the company's new materials segment saw increased shipments and gross profit for its main products, leading to significant year-on-year performance growth[30](index=30&type=chunk) [Tourism Business](index=14&type=section&id=%EF%BC%88%E4%BA%94%EF%BC%89%E6%97%85%E6%B8%B8%E4%B8%9A%E5%8A%A1) The tourism business covers scenic area cableways, transportation, hotels, and performances, leveraging multiple 5A-rated scenic areas like Lijiang Yulong Snow Mountain; despite some scenic areas being affected by adverse weather, the company optimized its operating strategies to achieve year-round operations, resulting in stable overall profit growth for the tourism segment - Despite revenue declines in some scenic areas due to weather factors, the company's efforts to achieve year-round operations in certain areas led to stable overall profit growth for the tourism segment compared to the previous year[30](index=30&type=chunk) [Analysis of Core Competencies](index=14&type=section&id=%E4%BA%8C%E3%80%81%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company has established distinct competitive advantages across all its business segments, including strong independent R&D and brand barriers in pharmaceuticals, a differentiated health industry ecosystem and talent advantage in medical services, product portfolio and R&D strengths in agrochemicals, leading technology accumulation and integrated supply chain in new materials, and superior resource integration and brand presence in tourism [Core Competencies of Pharmaceutical Business](index=14&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E5%8C%BB%E8%8D%AF%E4%B8%9A%E5%8A%A1) The pharmaceutical business's core competitiveness stems from nearly three decades of independent R&D accumulation, a deeply ingrained brand image, a comprehensive omni-channel marketing network, a digital high-end manufacturing platform, and an integrated API and formulation production model, collectively forming the company's competitive barriers in this field - The company boasts a pharmaceutical R&D team of nearly **400 professionals** and multiple national and provincial-level R&D platforms, having successfully developed **2 Class 1 new drugs and over 20 first-generic drugs**[51](index=51&type=chunk) - The company has established a nationwide self-built omni-channel marketing system and is actively expanding into new marketing channels such as e-commerce[52](index=52&type=chunk) [Core Competencies of Medical Business](index=15&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E5%8C%BB%E7%96%97%E4%B8%9A%E5%8A%A1) The medical business's core competitiveness lies in its differentiated, multi-tiered, full-lifecycle health management services built upon its health industry ecosystem, attracting numerous top-tier and international medical experts, and strategically locating its medical institutions in urban core areas, providing a significant geographical advantage - The company has established a health industry ecosystem encompassing basic medical care, rehabilitation, health management, and anti-aging/longevity services, enabling it to provide differentiated, multi-tiered, full-lifecycle health management services[54](index=54&type=chunk) [Core Competencies of Agrochemical Business](index=16&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%E5%86%9C%E5%8C%96%E4%B8%9A%E5%8A%A1) The agrochemical business's core competencies include a rich product portfolio, a robust independent R&D and innovation system (including a leading GLP laboratory in mainland China), strategic production base layouts across multiple provinces, and stable cooperative relationships with globally renowned agrochemical enterprises - The company offers over **100 products** across three major categories: herbicides, fungicides, and insecticides, holding a leading market share in China[57](index=57&type=chunk) - The company's Beijing GLP laboratory is a **leading pesticide GLP laboratory in mainland China**, enjoying a strong reputation in the industry[57](index=57&type=chunk) [Core Competencies of New Materials Business](index=16&type=section&id=%EF%BC%88%E5%9B%9B%EF%BC%89%E6%96%B0%E6%9D%90%E6%96%99%E4%B8%9A%E5%8A%A1) The new materials business's core competitiveness is rooted in its profound technical accumulation and process advantages, particularly in the thionyl chloride and its downstream products sector, supported by a comprehensive R&D mechanism, an integrated industrial chain strategy, cost advantages from economies of scale, and stable customer relationships with industry giants - The company possesses a solid technical foundation in the **m-/p-phthaloyl chloride chemical industry** and has led or participated in the formulation of multiple industry standards[59](index=59&type=chunk) - The company has established strong cooperative relationships with leading aramid manufacturers such as **Teijin (Japan), Kolon (Korea), and Tayho Advanced Materials**[62](index=62&type=chunk) [Core Competencies of Tourism Business](index=17&type=section&id=%EF%BC%88%E4%BA%94%EF%BC%89%E6%97%85%E6%B8%B8%E4%B8%9A%E5%8A%A1) The tourism business's core competitiveness lies in its strong resource integration capabilities, enabling it to provide integrated "eat, stay, travel, play, entertain, shop" services; the company operates core tourism businesses in multiple 5A-rated scenic areas and owns high-end brand hotels like Lijiang H&F InterContinental Resort, giving it a significant market competitive advantage - The company has a comprehensive business chain, integrating scenic area cableways, transportation, hotels, and performances to achieve synergistic effects[63](index=63&type=chunk) [Analysis of Principal Operations](index=17&type=section&id=%E4%B8%89%E3%80%81%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) During the reporting period, the company's total revenue slightly increased by 0.39%, with the agrochemical and new materials sector revenue growing by 3.52% as the main driver, while pharmaceutical sector revenue declined by 4.16%; in terms of profitability, the pharmaceutical sector boasted a high gross margin of 78.59%, increasing by 2.68 percentage points year-on-year, whereas the agrochemical and new materials sector had a lower gross margin of 14.08% Expense Analysis | Expense Item | Current Reporting Period (CNY) | YoY Change | | :--- | :--- | :--- | | Selling Expenses | 679,396,280.23 | 6.83% | | Administrative Expenses | 514,113,021.04 | -13.13% | | Financial Expenses | 109,606,590.81 | -21.38% | | R&D Investment | 208,763,883.52 | -3.27% | Revenue by Industry Segment | Industry Segment | Operating Revenue (CNY) | % of Total Revenue | YoY Change | | :--- | :--- | :--- | :--- | | Pharmaceutical Industry | 1,625,024,546.38 | 27.33% | -4.16% | | Agrochemical & New Materials Industry | 3,378,138,480.03 | 56.82% | 3.52% | | Tourism Services Industry | 492,836,775.84 | 8.29% | -1.53% | | Medical Services Industry | 191,041,078.70 | 3.21% | 16.55% | [Analysis of Non-Principal Operations](index=19&type=section&id=%E5%9B%9B%E3%80%81%E9%9D%9E%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) During the reporting period, non-principal operations positively contributed to total profit, with investment income reaching CNY 45.60 million, accounting for 6.60% of total profit, primarily from associate companies and wealth management products, while non-operating income of CNY 32.44 million, mainly from government grants and technical compensation, is not sustainable Non-Principal Operations Contribution | Item | Amount (CNY) | % of Total Profit | Reason for Formation | | :--- | :--- | :--- | :--- | | Investment Income | 45,604,511.88 | 6.60% | Investment income from associate companies, wealth management products, etc | | Non-Operating Income | 32,436,279.10 | 4.69% | Government grants, technical compensation received, etc | [Analysis of Assets and Liabilities](index=19&type=section&id=%E4%BA%94%E3%80%81%E8%B5%84%E4%BA%A7%E5%8F%8A%E8%B4%9F%E5%80%BA%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) As of the end of the reporting period, the company's total assets were CNY 29.65 billion, a slight increase of 0.69% from the end of the previous year, maintaining a stable asset-liability structure, with increases in monetary funds and accounts receivable, fixed assets accounting for the highest proportion at 27.28%, and CNY 3.578 billion in restricted assets primarily used for pledged and mortgaged borrowings - The company's asset composition showed no significant changes, with **fixed assets and long-term equity investments** being the non-current assets with the highest proportion[71](index=71&type=chunk) - As of the end of the period, the company had **CNY 3.578 billion in restricted assets**, primarily monetary funds, fixed assets, intangible assets, and long-term equity investments, used as collateral for borrowings[74](index=74&type=chunk) [Analysis of Investment Status](index=20&type=section&id=%E5%85%AD%E3%80%81%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) During the reporting period, the company's investment amounted to CNY 393 million, a 37.24% decrease year-on-year, with no significant equity or non-equity investments undertaken; to mitigate exchange rate risks, the company engaged in derivative investments for hedging purposes, including options, swaps, and forward contracts, totaling approximately CNY 405 million at period-end - The investment amount for the reporting period was **CNY 393 million**, a **37.24% decrease** compared to CNY 626 million in the same period last year[75](index=75&type=chunk) - The company engaged in derivative investments for hedging purposes to mitigate exchange rate risks, with the period-end investment amount accounting for **2.54% of the company's net assets**[79](index=79&type=chunk) [Analysis of Major Holding and Participating Companies](index=22&type=section&id=%E5%85%AB%E3%80%81%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) During the reporting period, core subsidiaries showed varied performance: Huabong Pharma contributed CNY 303 million in net profit, serving as the primary profit driver; Yingtai Bio achieved CNY 12.96 million in net profit, with performance stabilizing; Kaisheng New Materials and Yulong Snow Mountain also contributed CNY 88.48 million and CNY 128 million in net profit, respectively, demonstrating stable performance Performance of Major Subsidiaries | Company Name | Type | Operating Revenue (CNY) | Net Profit (CNY) | | :--- | :--- | :--- | :--- | | Huabong Pharma | Subsidiary | 1,183,571,839.46 | 303,443,992.59 | | Yingtai Bio | Subsidiary | 2,966,387,661.78 | 12,962,119.77 | | Hanjiang Pharma | Subsidiary | 209,662,344.30 | 74,465,486.26 | | Kaisheng New Materials | Subsidiary | 532,553,352.71 | 88,484,924.76 | | Yulong Snow Mountain | Subsidiary | 439,388,445.40 | 127,527,822.99 | [Risks Faced by the Company and Countermeasures](index=23&type=section&id=%E5%8D%81%E3%80%81%E5%85%AC%E5%8F%B8%E9%9D%A2%E4%B8%B4%E7%9A%84%E9%A3%8E%E9%99%A9%E5%92%8C%E5%BA%94%E5%AF%B9%E6%8E%AA%E6%96%BD) The company has comprehensively reviewed the main risks across its five major business segments: the pharmaceutical business faces risks from centralized procurement price reductions; the medical business faces policy and medical incident risks; the agrochemical and new materials businesses face safety production, environmental, and raw material price fluctuation risks; and the tourism business faces safety, market competition, and force majeure risks, with corresponding countermeasures developed for each - The pharmaceutical business faces price reduction risks due to the normalization of centralized drug procurement, which the company addresses by advancing consistency evaluations, improving its product pipeline, and expanding into the retail market[86](index=86&type=chunk) - The agrochemical and new materials businesses face risks from production safety, stricter environmental policies, and raw material price fluctuations, which the company addresses by strengthening internal management, increasing environmental protection investments, and adjusting sales prices[88](index=88&type=chunk)[89](index=89&type=chunk)[91](index=91&type=chunk) - The tourism business faces risks such as cableway safety, market competition, and force majeure events like natural disasters, which the company addresses by improving safety management systems, integrating operations to enhance competitiveness, and strengthening operational management[94](index=94&type=chunk)[95](index=95&type=chunk) [Corporate Governance, Environment, and Society](index=26&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) This section details the company's corporate governance structure, its environmental protection efforts, and its commitment to social responsibility [Corporate Governance](index=26&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E7%9B%91%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the company experienced changes in some directors, supervisors, and senior management due to re-election, with Peng Yunhui and Wang Zhengjun departing upon term expiration, Wang Xi elected as a new director, and Hu Jingjing appointed as the new Board Secretary - On May 14, 2025, the company experienced changes in multiple directors, supervisors, and senior management personnel, including the replacement of the Board Secretary, due to re-election[100](index=100&type=chunk) [Profit Distribution](index=26&type=section&id=%E4%BA%8C%E3%80%81%E6%9C%AC%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E5%8F%8A%E8%B5%84%E6%9C%AC%E5%85%AC%E7%A7%AF%E9%87%91%E8%BD%AC%E5%A2%9E%E8%82%A1%E6%9C%AC%E6%83%85%E5%86%B5) The company's board approved the 2025 half-year profit distribution plan, proposing a cash dividend of CNY 2.0 (tax inclusive) per 10 shares based on the total share capital after deducting repurchased shares, totaling approximately CNY 395 million in cash, with no bonus shares or capital reserve conversion Profit Distribution Plan | Distribution Plan | Content | | :--- | :--- | | Dividend per 10 shares (CNY) (tax inclusive) | 2.0 | | Share Capital Base for Distribution Plan (shares) | 1,972,852,683 | | Total Cash Dividend Amount (CNY) (tax inclusive) | 394,570,536.60 | | Proportion of Total Cash Dividend to Total Profit Distribution | 100% | [Environment and Social Responsibility](index=26&type=section&id=%E5%9B%9B%E3%80%81%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E6%83%85%E5%86%B5) The company and its 13 major subsidiaries are included in the list of enterprises required to disclose environmental information by law, with provided inquiry indexes; in terms of social responsibility, the company actively responds to rural revitalization policies through unit assistance, dispatching work teams, and industrial support, and has launched public welfare initiatives such as "Salute to Guardians" - The company and its **13 major subsidiaries** are included in the list of enterprises required to disclose environmental information by law, demonstrating the company's commitment to environmental compliance[105](index=105&type=chunk)[107](index=107&type=chunk) - The company actively fulfills its social responsibilities by supporting rural revitalization through various means and conducting special public welfare initiatives such as **"Salute to Guardians" and "Skin Health Campus Tour"**[108](index=108&type=chunk) [Significant Matters](index=28&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) This section outlines the company's major legal proceedings, significant contracts, and investment activities during the reporting period [Litigation Matters](index=28&type=section&id=%E5%85%AB%E3%80%81%E8%AF%89%E8%AE%BC%E4%BA%8B%E9%A1%B9) During the reporting period, the company had no significant litigation or arbitration matters; there were other lawsuits not meeting the significance threshold, with the company as plaintiff involving approximately CNY 27.05 million and as defendant involving approximately CNY 295.82 million, none of which are expected to have a material impact on the company's overall operations Litigation Overview | Litigation Role | Amount Involved (million CNY) | Impact | | :--- | :--- | :--- | | As Plaintiff | 27.052 | No significant impact | | As Defendant | 295.8216 | No significant impact | [Significant Guarantees](index=30&type=section&id=%E5%8D%81%E4%BA%8C%E3%80%81%E9%87%8D%E5%A4%A7%E5%90%88%E5%90%8C%E5%8F%8A%E5%85%B6%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) As of the end of the reporting period, the company's total actual guarantees amounted to CNY 3.669 billion, representing 37.63% of its net assets; these guarantees primarily support subsidiaries' daily operations and project financing, with CNY 451 million provided for entities whose debt-to-asset ratio exceeded 70% Guarantee Details | Guarantee Situation | Amount (million CNY) | | :--- | :--- | | Total Actual Guarantee Balance at Period-End | 3,668.683 | | Proportion of Total Actual Guarantees to Company's Net Assets | 37.63% | | Debt Guarantee Balance Provided for Guaranteed Parties with Debt-to-Asset Ratio Exceeding 70% | 451.0328 | [Wealth Management](index=35&type=section&id=3%E3%80%81%E5%A7%94%E6%89%98%E7%90%86%E8%B4%A2) During the reporting period, the company engaged in wealth management using both自有资金 and募集资金, with a total transaction amount of CNY 1.932 billion; as of the period-end, the outstanding balance was CNY 1.347 billion, primarily in bank and brokerage wealth management products, with no overdue amounts Wealth Management Products | Specific Type | Wealth Management Transaction Amount (million CNY) | Unexpired Balance (million CNY) | | :--- | :--- | :--- | | Bank Wealth Management Products | 1,767.5206 | 1,217.0512 | | Brokerage Wealth Management Products | 164.00 | 130.00 | | **Total** | **1,931.5206** | **1,347.0512** | [Share Changes and Shareholder Information](index=37&type=section&id=%E7%AC%AC%E5%85%AD%E8%8A%82%20%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E5%8F%8A%E8%82%A1%E4%B8%9C%E6%83%85%E5%86%B5) This section details changes in the company's share capital and provides an overview of its shareholder structure [Share Changes](index=37&type=section&id=%E4%B8%80%E3%80%81%E8%82%A1%E4%BB%BD%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the company's total share capital of 1,979,919,191 shares remained unchanged, while restricted shares increased by 609,575 due to changes in directors, supervisors, and senior management personnel and their share lock-up rules, with unrestricted shares decreasing accordingly - The company's total share capital remained unchanged, with minor adjustments in share structure due to changes in directors, supervisors, and senior management personnel and their share lock-up requirements[143](index=143&type=chunk) [Shareholder Information](index=38&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5) As of the end of the reporting period, the company had 73,829 common shareholders; Chongqing Huibang Zhuoyuan Technology was the controlling shareholder with 18.71% equity, and Mr Zhang Songshan, the actual controller, directly held 5.91%; some holdings of the controlling shareholder and actual controller among the top ten shareholders were pledged Top Shareholders | Shareholder Name | Shareholding Percentage | Number of Shares Held | Number of Pledged Shares | | :--- | :--- | :--- | :--- | | Chongqing Huibang Zhuoyuan Technology Co Ltd | 18.71% | 370,449,804 | 185,000,000 | | Zhang Songshan | 5.91% | 117,095,583 | 61,910,000 | | Dong Xiaoming | 3.31% | 65,467,528 | 0 | | Zhang Yizhuo | 2.78% | 55,060,000 | 22,080,000 | [Bond-Related Information](index=41&type=section&id=%E7%AC%AC%E4%B8%83%E8%8A%82%20%E5%80%BA%E5%88%B8%E7%9B%B8%E5%85%B3%E6%83%85%E5%86%B5) This section provides details on the company's corporate bonds and related financial indicators [Corporate Bonds](index=41&type=section&id=%E4%BA%8C%E3%80%81%E5%85%AC%E5%8F%B8%E5%80%BA%E5%88%B8) In April 2025, the company privately issued a tranche of technology innovation exchangeable corporate bonds, abbreviated as "25 Huabong EB," with a total issuance amount of CNY 600 million, a 3-year term, and a coupon rate of 0.1%, exclusively for professional institutional investors Corporate Bond Details | Bond Abbreviation | Bond Code | Issue Date | Maturity Date | Bond Balance (million CNY) | Coupon Rate | | :--- | :--- | :--- | :--- | :--- | :--- | | 25 Huabong EB | 117227 | 2025-04-21 | 2028-04-22 | 600 | 0.1% | [Key Accounting Data and Financial Indicators (Bond-Related)](index=42&type=section&id=%E5%85%AD%E3%80%81%E6%88%AA%E8%87%B3%E6%8A%A5%E5%91%8A%E6%9C%9F%E6%9C%AB%E5%85%AC%E5%8F%B8%E8%BF%91%E4%B8%A4%E5%B9%B4%E7%9A%84%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) As of the end of the reporting period, the company's solvency indicators showed stable performance, with both the current ratio and quick ratio improving, the asset-liability ratio decreasing from 47.46% to 46.17%, and the interest coverage ratio significantly increasing from 4.12 times to 5.51 times, indicating enhanced earnings coverage of interest expenses Solvency Indicators | Item | End of Current Reporting Period / Current Reporting Period | End of Prior Year / Prior Year Period | Change | | :--- | :--- | :--- | :--- | | Current Ratio | 1.23 | 1.08 | 13.89% | | Asset-Liability Ratio | 46.17% | 47.46% | -1.29% | | Interest Coverage Ratio | 5.51 | 4.12 | 33.74% | | Cash Interest Coverage Ratio | 3.50 | 2.07 | 69.08% | [Financial Report](index=43&type=section&id=%E7%AC%AC%E5%85%AB%E8%8A%82%20%E8%B4%A2%E5%8A%A1%E6%8A%A5%E5%91%8A) This section presents the company's financial statements and detailed notes, providing a comprehensive view of its financial position and performance [Financial Statements](index=43&type=section&id=%E4%BA%8C%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) This chapter includes the company's unaudited 2025 half-year consolidated and parent company financial statements, comprising the balance sheet, income statement, cash flow statement, and statement of changes in owners' equity, which comprehensively reflect the company's financial position at the end of the reporting period and its operating results and cash flows during the period - The company's half-year financial report is unaudited[164](index=164&type=chunk) [Notes to Financial Statements](index=57&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) This chapter elaborates on the company's basic information, the basis for preparing its financial statements, a statement of compliance with accounting standards, and significant accounting policies and estimates, while also providing detailed notes and explanations for key items within the consolidated financial statements, which are crucial for understanding the financial report - The company's business nature primarily includes pesticides, pharmaceuticals, chemical raw materials, medical health, and tourism services[193](index=193&type=chunk) - The company's actual controller is Mr Zhang Songshan, and the largest shareholder is Chongqing Huibang Zhuoyuan Technology Co Ltd[194](index=194&type=chunk) [Other Submitted Data](index=148&type=section&id=%E7%AC%AC%E4%B9%9D%E8%8A%82%20%E5%85%B6%E4%BB%96%E6%8A%A5%E9%80%81%E6%95%B0%E6%8D%AE) This section provides additional data submitted by the company, including investor relations activities [Investor Relations Activities](index=148&type=section&id=%E4%BA%8C%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%8E%A5%E5%BE%85%E8%B0%83%E7%A0%94%E3%80%81%E6%B2%9F%E9%80%9A%E3%80%81%E9%87%87%E8%AE%BF%E7%AD%89%E6%B4%BB%E5%8A%A8%E7%99%BB%E8%AE%B0%E8%A1%A8) During the reporting period, on April 25, 2025, the company hosted an online event to engage with various institutional and individual investors, primarily discussing its recent production and operational status and long-term development plans - The company conducted one online investor relations activity during the reporting period, engaging with investors on its operational status and development plans[647](index=647&type=chunk)

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 基于华邦生命健康股份有限公司（以下简称"公司"）收到控股股东重庆汇邦 卓远科技有限公司（曾用名：西藏汇邦科技有限公司）关于 2025 年中期分红的 提议，公司已于 2025 年 4 月 23 日在巨潮资讯网（www.cninfo.com.cn）刊载《关 于收到控股股东 2025 年中期分红提议的公告》（公告编号：2025024），为提升公 司投资价值、与投资者共享企业发展成果，公司拟定了 2025 年中期利润分配预 案。 一、审议程序 2025 年 8 月 18 日，公司召开董事会审计委员会 2025 年第二次会议、第九 届董事会第二次会议，审议通过了《2025 年中期利润分配预案》，本预案尚需提 交公司 2025 年第一次临时股东会审议。 二、利润分配预案基本情况 证券代码：002004 证券简称：华邦健康 公告编号：2025038 华邦生命健康股份有限公司 2025年中期利润分配预案 1、董事会审计委员会 2025 年第二次会议决议； 2、第九届董事会第二次会议决议。 特此公告。 2、根据公司 2025 年半 ...

每经AI快讯，8月19日，华邦健康（002004）公告称，华邦健康发布2025年半年度报告，公司实现营业 收入59.45亿元，同比增长0.39%；归属于上市公司股东的净利润为3.88亿元，同比增长23.90%。 ...

Group 1 - The meeting between US President Trump and Ukrainian President Zelensky is scheduled for August 18, with potential follow-up discussions involving US, Russia, and Ukraine leaders [2] - A-share indices reached new highs, with market analysts suggesting a focus on sectors like AI, innovative pharmaceuticals, non-ferrous metals, military industry, and large finance [2] - The upcoming National Day and Mid-Autumn Festival will have an 8-day holiday, with toll-free travel for small passenger vehicles on all toll roads [3] Group 2 - A-share market has seen a significant increase in stocks doubling in value, with over 310 stocks rising more than 100% this year, particularly in the pharmaceutical and machinery sectors [4] - CITIC Securities reports that market sentiment remains strong, with a focus on sectors such as innovative pharmaceuticals, resources, communications, military, and gaming [4] - As of August 15, 52.44% of funds established in 2021 have a net asset value above 1, indicating a recovery in the A-share market [5] Group 3 - Publicly offered funds of funds (FOFs) have shown strong performance this year, with 29 FOFs achieving over 20% returns, driven by heavy investments in high-volatility equity funds [6] - Notable private equity fund managers have increased their holdings in A-share companies, with significant investments in firms like Angel Yeast and Dao Technology [6] Group 4 - 25 companies listed on the Beijing Stock Exchange reported their 2025 semi-annual results, with 22 companies showing revenue growth, led by Zhuozhao Point Glue with a 207.46% increase [7] - China Shenhua, a state-owned enterprise, announced a major asset restructuring involving the acquisition of 10 companies and significant coal and energy assets [7] Group 5 - Hong Kong's financial secretary highlighted the ongoing development of a commodity trading ecosystem, aiming to position Hong Kong as an international gold trading center [19] - The first issuance of yen-denominated stablecoin JPYC is expected to be approved by Japan's Financial Services Agency, supporting its value with government bonds [13]

华邦健康8月4日股价报4.41元，与前一交易日持平。当日开盘价为4.42元，最高触及4.44元，最低下探 4.34元，成交量为232683手，成交金额达1.02亿元。 8月3日公司在投资者互动平台表示，针对基孔肯雅热患者的具体用药需由专业医疗人员确定。同时确认 了复方樟脑乳膏的驱蚊防护功效。 8月4日主力资金净流入538.35万元，近五日主力资金累计净流入2142.40万元。 风险提示：股市有风险，投资需谨慎。 该公司主营业务涵盖医药健康、农化、新材料等领域。在医药板块，华邦健康拥有皮肤科、结核科等系 列产品。公司生产的华邦复方樟脑乳膏具有驱蚊防护、叮咬止痒的作用。此外，其抗组胺药品如盐酸左 西替利嗪片等对缓解皮肤瘙痒有一定帮助。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司皮肤类产品对基孔肯雅热能改善吗，防治蚊虫叮 咬有用吗？ 华邦健康（002004.SZ）8月3日在投资者互动平台表示，公司生产的盐酸左西替利嗪片/口服液、苯磺贝 他斯汀片、阿伐斯汀胶囊等抗组胺药品对缓解皮肤瘙痒有一定帮助，但基孔肯雅热患者的具体用药需由 专业医疗人员结合患者临床症状确定。同时，公司生产的华邦复方樟脑乳膏具有驱蚊防护、叮咬止痒的 作用。 ...